In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
The Bridge to your success
slider, Sponsored PublicationsCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Biologics CDMO Rezon Bio leaves stealth mode
Latest NewsRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.
ProPure™: Raising the Bar in Life Science Research
slider, Sponsored PublicationsIn biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
Genmab swallows Merus in US$8bn deal
Latest NewsDanish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab
MSD Secures Option on EVX-B3
Latest NewsDanish Evaxion A/S hat optionally licenced its vaccine EVX-B3.developed with its AI-Immunology™ platform to Merck, Sharp & Dohme. MSD payed UIS$7.5m upfront and offers up to US$592m in milestone payments plus royalties on net sales.
Trump Targets Overseas with 100%-Tariff
Latest NewsOvernight, US President Donald Trump broke previous tariff agreements with the United Kingdom and the EU, announcing that from 1 October, patented medicines not produced in the US will be subject to a 100% tariff.
UniQure’s stocks up after AMT-130 trial win
Latest NewsAmsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for marketing authorisation next year. In addition, UniQure entered into a US$175m non-dilutive senior secured term loan facility with Hercules Capital and commenced a US$200m underwritten public offering of its ordinary shares to prepare a BLA in Q1 2026.
Siemens Healthineers enters CRISPR diagnostics space
Latest NewsSiemens Healthineers have participated in a US$25m Series A extension of the CRISPR diagnostics specialist VedaBio Inc and signed a strategic agreement.
Revyve scaling up production by €24m financing
Latest NewsWageningen-based food-tech scale-up Revyve has raised €24m in a Series B financing, bringing its total capital raised to more than €40 million. The company will use the proceeds to scale up its yeast-based egg replacement to the 1,600 t/a scale.
Roche moves obesity asset CT-388 into Phase III
Latest NewsSwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by 2030, Roche Pharma CEO Teresa Graham said at Roche’s Pharma Day in London.